EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells

Chung-Pu Wu iD, Yen-Ching Li, Megumi Murakami iD, Sung-Han Hsiao, Yun-Chieh Lee, Yang-Hui Huang, Yu-Tzu Chang, Tai-Ho Hung, Yu-Shan Wu iD, Suresh V Ambudkar iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241813972 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Chung-Pu Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily G, Member 2, Drug Resistance, Neoplasm, Neoplasm Proteins, Drug Resistance, Multiple. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan, National Science and Technology Council, Taiwan, Chang Gung Memorial Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ATP-binding cassette transporters, including ABCB1 (P-glycoprotein) and ABCG2 (BCRP/MXR/ABCP), are pivotal in multidrug resistance (MDR) development in cancer patients undergoing conventional chemotherapy. The absence of approved therapeutic agents for multidrug-resistant cancers presents a significant challenge in effectively treating cancer. Researchers propose repurposing existing drugs to sensitize multidrug-resistant cancer cells, which overexpress ABCB1 or ABCG2, to conventional anticancer drugs. The goal of this study is to assess whether furmonertinib, a third-generation epidermal growth factor receptor tyrosine kinase inhibitor overcomes drug resistance mediated by ABCB1 and ABCG2 transporters. Furmonertinib stands out due to its ability to inhibit drug transport without affecting protein expression. The discovery of this characteristic was validated through ATPase assays, which revealed interactions between furmonertinib and ABCB1/ABCG2. Additionally, in silico docking of furmonertinib offered insights into potential interaction sites within the drug-binding pockets of ABCB1 and ABCG2, providing a better understanding of the underlying mechanisms responsible for the reversal of MDR by this repurposed drug. Given the encouraging results, we propose that furmonertinib should be explored as a potential candidate for combination therapy in patients with tumors that have high levels of ABCB1 and/or ABCG2. This combination therapy holds the potential to enhance the effectiveness of conventional anticancer drugs and presents a promising strategy for overcoming MDR in cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP Binding Cassette Transporter, Subfamily G, Member 2Drug Resistance, NeoplasmNeoplasm ProteinsDrug Resistance, MultipleProtein Kinase InhibitorsAntineoplastic AgentsNeoplasmsHumansATP Binding Cassette Transporter, Subfamily BMolecular Docking SimulationCell Line, TumorErbB ReceptorsTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

ABC transporterABCB1ABCG2drug repurposingfurmonertinibmultidrug resistance

Substanzen

ATP Binding Cassette Transporter, Subfamily G, Member 2Neoplasm ProteinsProtein Kinase InhibitorsABCG2 protein, humanABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BErbB ReceptorsAntineoplastic AgentsEGFR protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Graduate Institute of Biomedical Sciences, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
  • Department of Physiology and Pharmacology, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
  • Molecular Medicine Research Center, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.
  • Department of Obstetrics and Gynecology, Taipei Chang Gung Memorial Hospital, Taipei 10507, Taiwan.
  • Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
  • Department of Medicine, College of Medicine, Chang Gung University, Taoyuan 33302, Taiwan.

ORCID-Profile: Chung-Pu Wu, Megumi Murakami, Yu-Shan Wu, Suresh V Ambudkar

Förderung

  • Ministry of Science and Technology, Taiwan
  • National Science and Technology Council, Taiwan
  • Chang Gung Memorial Hospital
  • National Cancer Institute, Center for Cancer Research
  • the Ministry of Science and Technology, Taiwan
  • the National Science and Technology Council, Taiwan
  • the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Center for Cancer Research

Zitieren

APA

Wu, C. P., Li, Y. C., Murakami, M., Hsiao, S. H., Lee, Y. C., Huang, Y. H., Chang, Y. T., Hung, T. H., Wu, Y. S., & Ambudkar, S. V. (2023). Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241813972

Vancouver

Wu CP, Li YC, Murakami M, Hsiao SH, Lee YC, Huang YH, et al. Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241813972

BibTeX
@article{Wu2023,
  author = {Wu, Chung-Pu and Li, Yen-Ching and Murakami, Megumi and Hsiao, Sung-Han and Lee, Yun-Chieh and Huang, Yang-Hui and Chang, Yu-Tzu and Hung, Tai-Ho and Wu, Yu-Shan and Ambudkar, Suresh V},
  title = {Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241813972}
}
Kostenlos starten →